125 related articles for article (PubMed ID: 31478892)
1. The Dose and Timing of Fentanyl Impacts on Ticagrelor Absorption and Platelet Inhibition During Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial.
Goli RR; Ibrahim K; Shah R; Kickler TS; Clarke WA; Resar JR; Schulman SP; McEvoy JW
J Invasive Cardiol; 2019 Sep; 31(9):265-271. PubMed ID: 31478892
[TBL] [Abstract][Full Text] [Related]
2. Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial.
Ibrahim K; Shah R; Goli RR; Kickler TS; Clarke WA; Hasan RK; Blumenthal RS; Thiemann DR; Resar JR; Schulman SP; McEvoy JW
Thromb Haemost; 2018 Aug; 118(8):1409-1418. PubMed ID: 29972861
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: Design, rationale, and sample characteristics of the PACIFY randomized trial.
Ibrahim K; Goli RR; Shah R; Resar JR; Schulman SP; McEvoy JW
Contemp Clin Trials; 2018 Jan; 64():8-12. PubMed ID: 29170073
[TBL] [Abstract][Full Text] [Related]
4. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
[TBL] [Abstract][Full Text] [Related]
5. Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl).
McEvoy JW; Ibrahim K; Kickler TS; Clarke WA; Hasan RK; Czarny MJ; Keramati AR; Goli RR; Gratton TP; Brinker JA; Chacko M; Hwang CW; Johnston PV; Miller JM; Trost JC; Herzog WR; Blumenthal RS; Thiemann DR; Resar JR; Schulman SP
Circulation; 2018 Jan; 137(3):307-309. PubMed ID: 29046319
[No Abstract] [Full Text] [Related]
6. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
[TBL] [Abstract][Full Text] [Related]
7. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
[TBL] [Abstract][Full Text] [Related]
8. Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
Franchi F; Rollini F; Park Y; Hu J; Kureti M; Rivas Rios J; Faz G; Yaranov D; Been L; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2019 Aug; 12(16):1538-1549. PubMed ID: 31377269
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial.
Iglesias JF; Valgimigli M; Carbone F; Lauriers N; Masci PG; Degrauwe S
Cardiol J; 2022; 29(4):591-600. PubMed ID: 35762079
[TBL] [Abstract][Full Text] [Related]
10. Response by Ibrahim et al to Letter Regarding Article, "Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)".
Ibrahim K; Shah R; McEvoy JW
Circulation; 2018 Jul; 138(2):216-217. PubMed ID: 29986967
[No Abstract] [Full Text] [Related]
11. Letter by Kikkert et al Regarding Article, "Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)".
Kikkert WJ; Delewi R; Claessen BEPM
Circulation; 2018 Jul; 138(2):214-215. PubMed ID: 29986966
[No Abstract] [Full Text] [Related]
12. Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS).
Musallam A; Orvin K; Perl L; Mosseri M; Arbel Y; Roguin A; Lev EI
Can J Cardiol; 2016 Oct; 32(10):1246.e13-1246.e19. PubMed ID: 26971236
[TBL] [Abstract][Full Text] [Related]
13. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
14. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R
J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
Alexopoulos D; Kontoprias K; Gkizas V; Karanikas S; Ziakas A; Barampoutis N; Tsigkas G; Koutsogiannis N; Davlouros P; Patsilinakos S; Karvounis H; Hahalis G; Xanthopoulou I
Platelets; 2016 Jul; 27(5):420-6. PubMed ID: 26763727
[TBL] [Abstract][Full Text] [Related]
17. Differential impact of fentanyl and morphine doses on ticagrelor-induced platelet inhibition in ST-segment elevation myocardial infarction: a subgroup analysis from the PERSEUS randomized trial.
Garin D; Degrauwe S; Carbone F; Musayeb Y; Lauriers N; Valgimigli M; Iglesias JF
Front Cardiovasc Med; 2024; 11():1324641. PubMed ID: 38628315
[TBL] [Abstract][Full Text] [Related]
18. Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial.
Asher E; Tal S; Mazin I; Abu-Much A; Sabbag A; Katz M; Regev E; Chernomordik F; Guetta V; Segev A; Elian D; Barbash I; Fefer P; Narodistky M; Beigel R; Matetzky S
JAMA Cardiol; 2017 Dec; 2(12):1380-1384. PubMed ID: 29071332
[TBL] [Abstract][Full Text] [Related]
19. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose.
Holm M; Tornvall P; Westerberg J; Rihan Hye S; van der Linden J
Platelets; 2017 Nov; 28(7):706-711. PubMed ID: 28150519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]